- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-radiographic axial spondyloarthritis; Severe active psoriatic arthritis; Severe psoriatic arthritis; Ankylosing spondylitis; Active ankylosing spondylitis; Severe chronic plaque psoriasis.
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 397KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 60KB)
Secukinumab – March 2022
Secukinumab: Solution for injection 300 mg in 2 mL pre-filled pen, Solution for injection 300 mg in 2 mL pre-filled syringe; Cosentyx®
Last updated
1 July 2022